Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

多供应商多站点新型加速 MRI 松弛测量

• 批准号: 10677551
• 负责人: Xiaojuan Li
• 金额: $ 60.37万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10677551
• 关键词: 3-Dimensional; Acceleration; Acute; Address; Affect; Age; Atlases; Behavior Therapy; Biological Markers; Body Weight decreased; Body mass index; Calibration; Cartilage; Clinical; Clinical Protocols; Collaborations; Data; Data Analyses; Dedications; Degenerative polyarthritis; Development; Diagnosis; Diet; Disease; Disease Progression; Early Diagnosis; Early treatment; Evaluation; Exercise; Gender; Image; Impairment; Industrialization; Intervention; Magnetic Resonance Imaging; Maps; Measurement; Measures; Methods; Modeling; Morphology; Musculoskeletal; Patients; Persons; Pharmaceutical Preparations; Pilot Projects; Prevention; Prevention strategy; Prognosis; Protocols documentation; Quality of life; Reference Values; Relaxation; Risk; Scanning; Site; Source; Standardization; System; T2 weighted imaging; Techniques; Technology; Time; Travel; Uncertainty; Variant; Vendor; anterior cruciate ligament rupture; cancer imaging; cartilage degradation; clinical practice; clinical translation; early detection biomarkers; heart imaging; human subject; imaging biomarker; imaging modality; improved; joint function; liver imaging; multi-site trial; musculoskeletal imaging; neural; neuroimaging; novel; palliation; precision medicine; quantitative imaging; synergism; tool; treatment effect

PROJECT SUMMARY/ABSTRACT MRI relaxometry has been applied to improve early diagnosis and prognosis for a wide range of diseases. However, one typical obstacle of integrating quantitative MRI into clinical protocols is the long acquisition time. Furthermore, it is an essential but sometimes overlooked step to investigate quantification variability across sites and MR systems in order to validate MR imaging biomarkers and to apply the measures in large scale multi- vendor multi-site trials. Specifically, there is a lack of systematic evaluation of inter-vendor inter-site variability of T1ρ imaging, even though it has been widely applied in neural-, liver-, cardiac-, oncology-, and musculoskeletal- (MSK) imaging. Neither commercial T1ρ phantoms are available. The proposed study is addressing these significant gaps and aims to develop and cross-validate novel fast MR T1ρ and T2 imaging methods on MR systems from multiple vendors, followed by feasibility evaluation in patients at risk for osteoarthritis. Osteoarthritis (OA) affects over 27 million people in the US. No disease modifying OA drugs (DMOADs) are available, despite extensive effort. One hurdle for developing DMOADs is the lack of sensitive and reliable non-invasive biomarkers that can detect treatment effects over a short time window. Such biomarkers would also benefit clinical practice by identifying patients at risk for developing OA or at an early disease stage, when behavior modification strategies are shown to be most effective in slowing down the disease progression. There is a pressing, unmet clinical need for robust assessment of early degeneration, which is critical to support a paradigm shift of OA management from palliation of late disease towards prevention through early diagnosis and early treatment/interventions. Cartilage MR T1ρ and T2 measures have been shown to be promising imaging biomarkers for early cartilage degeneration. However, many challenges remain to clinically applying these techniques, including lack of standardized acquisition and analysis methods, long acquisition time, and uncertainty of variations between different MR systems. In this study, we will develop novel accelerated T1ρ and T2 imaging methods, implement these techniques on MR systems of three major vendors (Siemens, GE and Philips), systematically evaluate inter-vendor inter-site variation of these measures using dedicated T1ρ and T2 calibration phantoms (to be developed in this study) and traveling subjects, investigate the source(s) and magnitude of the differences, explore methods to mitigate the variability, and demonstrate the feasibility of the newly developed acceleration techniques to quantify cartilage degeneration longitudinally in a multi-vendor setting. Successful implementation of the proposed study will provide a full package of T1ρ and T2 imaging that will be ready for dissemination and will help to pave the way towards large-scale multi-vendor, multi-site trials using T1ρ and T2 imaging, facilitate clinical translation of these quantitative MR techniques, and ultimately transform patient management of OA and other disorders using quantitative imaging biomarkers.

项目摘要/摘要 MRI松弛计已用于改善各种疾病的早期诊断和预后。 但是，将定量MRI整合到临床方案中的一个典型障碍是漫长的获取时间。 此外，这是研究网站之间数量可变性的必不可少但有时被忽略的一步 和MR系统以验证MR成像生物标志物并大规模应用多个措施 供应商多站点试验。具体而言，缺乏对供应商间间间可变性的系统评估 T1ρ成像，即使已广泛应用于神经，肝，心脏，肿瘤学和肌肉骨骼 - （MSK）成像。两种商业T1ρ幻影都没有可用。拟议的研究正在解决这些问题 在MR上开发和交叉估算新颖的快速MRT1ρ和T2成像方法的巨大差距和旨在跨越估计的差距 来自多个供应商的系统，然后对有骨关节炎风险的患者进行可行性评估。骨关节炎 （OA）影响美国超过2700万人。没有可修改OA药物（DMOADS）的疾病，dospite 巨大的努力。开发DMOADS的一个障碍是缺乏敏感和可靠的非侵入性生物标志物 这可以在短时间内检测治疗效果。这样的生物标志物也将使临床实践受益 通过识别患有OA或在早期疾病阶段的风险的患者，当行为改变时 证明策略在减慢疾病进展方面最有效。有一个紧迫的，未安装的 对早期变性的强大评估临床需求，这对于支持OA的范式转移至关重要 从抑制晚期疾病到预防到早期诊断和早期的治疗 治疗/干预措施。软骨MRT1ρ和T2测量已显示为有希望的成像 早期软骨变性的生物标志物。但是，在临床上仍然存在许多挑战 技术，包括缺乏标准化的获取和分析方法，长期获取时间以及 不同MR系统之间变化的不确定性。在这项研究中，我们将开发新的加速T1ρ和 T2成像方法，对三个主要供应商的MR系统实施这些技术（西门子，GE和 飞利浦），使用专用的T1ρ和T2系统地评估这些措施的供应商间差异 校准幻像（在本研究中开发）和旅行受试者，研究来源和来源 差异的幅度，探索减轻变异性的方法，并证明了可行性 新开发的加速技术以纵向量化软骨变性。 环境。拟议研究的成功实施将提供完整的T1ρ和T2成像包装 将准备好进行传播，并将有助于铺平道路朝大型多供应商，多站点试验铺平道路 使用T1ρ和T2成像，促进这些定量MR技术的临床翻译，并最终 使用定量成像生物标志物改变OA和其他疾病的患者管理。